Cargando…
Risk prediction of developing venous thrombosis in combined oral contraceptive users
BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531518/ https://www.ncbi.nlm.nih.gov/pubmed/28750087 http://dx.doi.org/10.1371/journal.pone.0182041 |
_version_ | 1783253376964755456 |
---|---|
author | McDaid, Aaron Logette, Emmanuelle Buchillier, Valérie Muriset, Maude Suchon, Pierre Pache, Thierry Daniel Tanackovic, Goranka Kutalik, Zoltán Michaud, Joëlle |
author_facet | McDaid, Aaron Logette, Emmanuelle Buchillier, Valérie Muriset, Maude Suchon, Pierre Pache, Thierry Daniel Tanackovic, Goranka Kutalik, Zoltán Michaud, Joëlle |
author_sort | McDaid, Aaron |
collection | PubMed |
description | BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. METHODS AND FINDINGS: Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. CONCLUSION: We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use. |
format | Online Article Text |
id | pubmed-5531518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55315182017-08-07 Risk prediction of developing venous thrombosis in combined oral contraceptive users McDaid, Aaron Logette, Emmanuelle Buchillier, Valérie Muriset, Maude Suchon, Pierre Pache, Thierry Daniel Tanackovic, Goranka Kutalik, Zoltán Michaud, Joëlle PLoS One Research Article BACKGROUND: Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. METHODS AND FINDINGS: Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. CONCLUSION: We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use. Public Library of Science 2017-07-27 /pmc/articles/PMC5531518/ /pubmed/28750087 http://dx.doi.org/10.1371/journal.pone.0182041 Text en © 2017 McDaid et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article McDaid, Aaron Logette, Emmanuelle Buchillier, Valérie Muriset, Maude Suchon, Pierre Pache, Thierry Daniel Tanackovic, Goranka Kutalik, Zoltán Michaud, Joëlle Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title | Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title_full | Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title_fullStr | Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title_full_unstemmed | Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title_short | Risk prediction of developing venous thrombosis in combined oral contraceptive users |
title_sort | risk prediction of developing venous thrombosis in combined oral contraceptive users |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531518/ https://www.ncbi.nlm.nih.gov/pubmed/28750087 http://dx.doi.org/10.1371/journal.pone.0182041 |
work_keys_str_mv | AT mcdaidaaron riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT logetteemmanuelle riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT buchilliervalerie riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT murisetmaude riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT suchonpierre riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT pachethierrydaniel riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT tanackovicgoranka riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT kutalikzoltan riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers AT michaudjoelle riskpredictionofdevelopingvenousthrombosisincombinedoralcontraceptiveusers |